Please login to the form below

Not currently logged in
Email:
Password:

cancer patients

This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.

Keytruda adds another NSCLC approval in Europe

Keytruda adds another NSCLC approval in Europe

With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA.”. ... The treatment has also seen recent success as a monotherapy in locally advanced or metastatic

Latest news

  • Gottlieb admonishes industry for clinical trial failings Gottlieb admonishes industry for clinical trial failings

    with efficacy signals being tested in small groups of patients based on biomarkers, could mean earlier access to important new medicines. ... That includes patients with brain metastases or previous malignancies, those with organ dysfunctions, and

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    Abraxane (nab-paclitaxel) is already approved to treat patients with advanced metastatic pancreatic cancer, but Celgene had been hoping to get approval for the drug as an adjuvant therapy given after ... Celgene also says that there are currently more

  • Lynparza scores against pancreatic cancer Lynparza scores against pancreatic cancer

    The FDA has already given Lynparza an orphan drug designation for the treatment of patients with BRCA-mutated pancreatic cancer, which AZ says is a “devastating disease with critical unmet need” ... It also is the first drug PARP inhibitor to show

  • FDA and Flatiron extend real world evidence collaboration FDA and Flatiron extend real world evidence collaboration

    The FDA's Richard Pazdur. In the first phase of the partnership, Flatiron provided the FDA with de-identified datasets to provide insights on cancer patients with advanced non-small cell ... We believe that regulatory-grade real-world data can help

  • More good news, and some bad, for Merck’s Keytruda More good news, and some bad, for Merck’s Keytruda

    The application is for accelerated approval based on the results of the KEYNOTE-158 trial, which showed that Keytruda, given as a monotherapy to SCLC patients whose cancer had progressed despite ... for head and neck cancer both as a monotherapy and in

More from news
Approximately 0 fully matching, plus 954 partially matching documents found.

Latest Intelligence

  • Genomics integration: can the NHS rise to the challenge? Genomics integration: can the NHS rise to the challenge?

    Last year, NHS England announced that it will focus on earlier diagnosis and more personalised medicines for cancer and rare disease patients, and it will further that goal by launching a ... The data has to be managed very carefully, with the benefits

  • Bringing life to precision medicine Bringing life to precision medicine

    Thus far, researchers have been unable to identify which cancer drug will work most effectively for specific patients, ie, precision medicine. ... A groundbreaking study in 2018 on patients with recurrent metastatic cancer showed that organoids are

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Around 10-20% of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence that the cancer has spread at the time of the ... In patients with non-metastatic CRPC, there is a high unmet need to delay development of

  • Is China ready for a pharmaceutical gold rush?

    With most lung cancer patients already at an advanced stage when diagnosed, prolonging survival is an important goal. ... Earlier this year, data showed Keytruda combined with chemotherapy could cut the risk of death among previously untreated lung

More from intelligence
Approximately 0 fully matching, plus 51 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... targeted cancer therapies and treating patients.

  • Taiho Oncology names Timothy Whitten as president Taiho Oncology names Timothy Whitten as president

    to focus on patients with cancer through the development of our robust pipeline and product commercialisation.”. ... I look forward to working with my colleagues at Taiho to ensure that patients continue to benefit from our products now and in the

More from appointments
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 56 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics